Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7905383 | 1.00 | CYP2C9 (0.47) | CYP2C9CYP2C8KDRCYP2D6PSEN1 | |
| SCHEMBL7743967 | 1.00 | CYP2C9 (0.47) | CYP2C9CYP2C8KDRCYP2D6PSEN1 | |
| SCHEMBL7743480 | 0.94 | CYP2C9 (0.44) | CYP2C9CYP2C8KDRCYP2D6PSEN1 | |
| SCHEMBL7712132 | 0.91 | CYP2C9 (0.42) | CYP2C9CYP2C8KDRCYP2D6PSEN1 | |
| SCHEMBL6816543 | 0.91 | CYP2C9 (0.42) | CYP2C9CYP2C8KDRCYP2D6PSEN1 | |
| SCHEMBL7737922 | 0.88 | CYP2C9 (0.44) | CYP2C9CYP2C8KDRCYP2D6PSEN1 | |
| SCHEMBL7074966 | 0.86 | CYP2C9 (0.40) | CYP2C9CYP2C8KDRCYP2D6MEN1 | |
| SCHEMBL7743932 | 0.85 | PDE2A (0.47) | CYP2C9CYP2C8CYP2D6MEN1MAPT | |
| SCHEMBL7908437 | 0.85 | CYP2C9 (0.43) | CYP2C9CYP2C8CYP2D6MEN1MAPT | |
| SCHEMBL7743339 | 0.85 | F7 (0.49) | CYP2C9CYP2C8CYP2D6MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6197803-B1 | VIRICIDES; PREVENTION REPRODUCTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-06 | — | — | US | claimed |
| US-12447207-B2 | Human cytomegalovirus gB polypeptide | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240299587-A1 | NOVEL DRUGGABLE REGIONS IN THE HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B POLYPEPTIDE AND METHODS OF USE THEREOF | PFIZER (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240100153-A1 | HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE | PFIZER (US) | 2024-03-28 | — | — | US | disclosed |
| CN-117677847-A | Novel patentable regions in human cytomegalovirus glycoprotein B polypeptides and methods of use thereof | 辉瑞公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11857622-B2 | Human cytomegalovirus GB polypeptide | PFIZER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-116348131-A | Human cytomegalovirus gB polypeptides | 辉瑞公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11629172-B2 | Human cytomegalovirus gB polypeptide | PFIZER INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20220088184-A1 | HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE | PFIZER INC. | 2022-03-24 | — | — | US | disclosed |
| US-20200247853-A1 | HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE | PFIZER INC. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447207-B2 | Human cytomegalovirus gB polypeptide | GBA3, HBB, PDGFA | CYP2C9 4334/4885CYP2C8 4354/4885KDR 1200/4885 |
| US-20240299587-A1 | NOVEL DRUGGABLE REGIONS IN THE HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B POLYPEPTIDE AND METHODS OF USE THEREOF | HAVCR2, LGALS3BP, GBA3 | CYP2C9 4158/4885CYP2C8 3261/4885KDR 1074/4885 |
| US-11629172-B2 | Human cytomegalovirus gB polypeptide | GBA3, HBB, PDGFA | CYP2C9 4616/4885CYP2C8 4278/4885KDR 1502/4885 |
| US-20240100153-A1 | HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE | GBA3, HBB, PDGFA | CYP2C9 4634/4885CYP2C8 4335/4885KDR 1541/4885 |
| US-20200247853-A1 | HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE | GBA3, HBB, PDGFA | CYP2C9 4616/4885CYP2C8 4278/4885KDR 1502/4885 |
| US-20220088184-A1 | HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE | GBA3, HBB, PDGFA | CYP2C9 4634/4885CYP2C8 4335/4885KDR 1541/4885 |
| US-11857622-B2 | Human cytomegalovirus GB polypeptide | GBA3, GLMN, HBB | CYP2C9 4580/4885CYP2C8 4367/4885KDR 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.